Press releases
- Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
- Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
- Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
- Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
- Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank
- Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 34.88 |
Average volume | -- |
---|---|
Shares outstanding | 23.12m |
Free float | 14.97m |
P/E (TTM) | -- |
Market cap | 1.25bn PLN |
EPS (TTM) | -4.10 PLN |
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼